Inclusion Criteria:

1. Aged 18-75 years old;

2. Pneumonia patients with SARS-CoV-2 infection were confirmed to be positive by RT-PCR
and clinical manifestations. The diagnosis standard refers to the diagnosis and
treatment plan for pneumonia with SARS-CoV-2 infection (Current Trial Version);

3. Patients with newly diagnosed respiratory system discomfort who have been hospitalized
(the diagnosis time of respiratory system discomfort shall not exceed 7 days);

4. Women and their partners who have no planned pregnancy for nearly half a year and are
willing to take effective contraceptive measures within 30 days from the first
administration of the study drug to the last administration;

5. Agree not to participate in other clinical research within 30 days from the first
administration of the study drug to the last administration;

6. Patients who voluntarily sign informed consent.

Exclusion Criteria:

1. The pneumonia patients with severe SARS-CoV-2 infection met one of the following
conditions: respiratory distress, RR≥30 times / min; or SaO2 / SpO2≤93% in resting
state; or arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2)
≤300MMHG (1mmhg = 0.133kpa);

2. Pneumonia patients with severe SARS-CoV-2 infection meet one of the following
conditions: respiratory failure and need mechanical ventilation; or shock; or other
organ failure combined with ICU monitoring treatment;

3. Severe liver disease (such as child Pugh score ≥C, AST > 5 times upper limit);

4. Patients with contraindications specified in the instructions of danoprevir and
ritonavir tablets;

5. Patients who plan to take protease inhibitors other than danoprevir and ritonavir
simultaneously during the trial.

6. The pregnancy test of female subjects in the screening period was positive;

7. The researchers judged that it was not suitable to participate in this clinical trial
(for example, patients who may be transferred to another hospital during the study
period; patients with multiple basic diseases, etc.).